Use of Graftskin (Apligraf®) in the Treatment of Pressure Ulcers and Acute Wounds

Harold Brem, Robert Kirsner

Research output: Contribution to journalArticle

3 Citations (Scopus)

Abstract

Graftskin (Apligraf®) is a tissue-engineered skin product that has been shown in randomized clinical trials to significantly accelerate healing in the treatment of venous ulcers, especially those greater than one year in duration, as well as diabetic foot ulcers. We hypothesize that it may also be effective in the treatment of other types of wounds, such as pressure ulcers and acute wounds. Furthermore, we hypothesize that Graftskin might be maximally effective when used in conjunction with other types of therapy. In this paper, we report on our results from the treatment with Graftskin of pressure ulcers and acute wounds. We show that stage II and III pressure ulcers rapidly heal after Graftskin application on an average of 29 days. Graftskin is also effective in the treatment of acute and chronic wounds. Graftskin is now part of the surgical armamentarium and should be used in conjunction with other standards of care, such as pressure relief, elimination of drainage, and the treatment of local infection.

Original languageEnglish
JournalWounds
Volume12
Issue number5 SUPPL. A
StatePublished - Dec 1 2000

Fingerprint

Pressure Ulcer
Wounds and Injuries
Therapeutics
Varicose Ulcer
Diabetic Foot
Standard of Care
Apligraf
Drainage
Randomized Controlled Trials
Pressure
Skin
Infection

ASJC Scopus subject areas

  • Surgery

Cite this

Use of Graftskin (Apligraf®) in the Treatment of Pressure Ulcers and Acute Wounds. / Brem, Harold; Kirsner, Robert.

In: Wounds, Vol. 12, No. 5 SUPPL. A, 01.12.2000.

Research output: Contribution to journalArticle

@article{17243284b8e14d80aee05c51229a2a2f,
title = "Use of Graftskin (Apligraf{\circledR}) in the Treatment of Pressure Ulcers and Acute Wounds",
abstract = "Graftskin (Apligraf{\circledR}) is a tissue-engineered skin product that has been shown in randomized clinical trials to significantly accelerate healing in the treatment of venous ulcers, especially those greater than one year in duration, as well as diabetic foot ulcers. We hypothesize that it may also be effective in the treatment of other types of wounds, such as pressure ulcers and acute wounds. Furthermore, we hypothesize that Graftskin might be maximally effective when used in conjunction with other types of therapy. In this paper, we report on our results from the treatment with Graftskin of pressure ulcers and acute wounds. We show that stage II and III pressure ulcers rapidly heal after Graftskin application on an average of 29 days. Graftskin is also effective in the treatment of acute and chronic wounds. Graftskin is now part of the surgical armamentarium and should be used in conjunction with other standards of care, such as pressure relief, elimination of drainage, and the treatment of local infection.",
author = "Harold Brem and Robert Kirsner",
year = "2000",
month = "12",
day = "1",
language = "English",
volume = "12",
journal = "Wounds",
issn = "1044-7946",
publisher = "HMP Communications",
number = "5 SUPPL. A",

}

TY - JOUR

T1 - Use of Graftskin (Apligraf®) in the Treatment of Pressure Ulcers and Acute Wounds

AU - Brem, Harold

AU - Kirsner, Robert

PY - 2000/12/1

Y1 - 2000/12/1

N2 - Graftskin (Apligraf®) is a tissue-engineered skin product that has been shown in randomized clinical trials to significantly accelerate healing in the treatment of venous ulcers, especially those greater than one year in duration, as well as diabetic foot ulcers. We hypothesize that it may also be effective in the treatment of other types of wounds, such as pressure ulcers and acute wounds. Furthermore, we hypothesize that Graftskin might be maximally effective when used in conjunction with other types of therapy. In this paper, we report on our results from the treatment with Graftskin of pressure ulcers and acute wounds. We show that stage II and III pressure ulcers rapidly heal after Graftskin application on an average of 29 days. Graftskin is also effective in the treatment of acute and chronic wounds. Graftskin is now part of the surgical armamentarium and should be used in conjunction with other standards of care, such as pressure relief, elimination of drainage, and the treatment of local infection.

AB - Graftskin (Apligraf®) is a tissue-engineered skin product that has been shown in randomized clinical trials to significantly accelerate healing in the treatment of venous ulcers, especially those greater than one year in duration, as well as diabetic foot ulcers. We hypothesize that it may also be effective in the treatment of other types of wounds, such as pressure ulcers and acute wounds. Furthermore, we hypothesize that Graftskin might be maximally effective when used in conjunction with other types of therapy. In this paper, we report on our results from the treatment with Graftskin of pressure ulcers and acute wounds. We show that stage II and III pressure ulcers rapidly heal after Graftskin application on an average of 29 days. Graftskin is also effective in the treatment of acute and chronic wounds. Graftskin is now part of the surgical armamentarium and should be used in conjunction with other standards of care, such as pressure relief, elimination of drainage, and the treatment of local infection.

UR - http://www.scopus.com/inward/record.url?scp=0008956885&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=0008956885&partnerID=8YFLogxK

M3 - Article

VL - 12

JO - Wounds

JF - Wounds

SN - 1044-7946

IS - 5 SUPPL. A

ER -